Semaglutide, a glucagon-like peptide 1 receptor agonist, may have a therapeutic role by targeting common mechanisms involved in the pathophysiology of T2D and NAFLD. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.